ClinicalTrials.gg
RecruitingNCT07858799ALT-FLOW HFrEFUpdated Oct 5, 2026

Early Feasibility Study of the Edwards APTURE Transcatheter Shunt System

An interventional study of Edwards APTURE transcatheter shunt system in Heart Failure, sponsored by Edwards Lifesciences. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Heart Failure by Edwards Lifesciences — 4 open to participants now, 10 under way, none of them phase 3. Heart Failure · Edwards Lifesciences.

Planned enrollment
13th of 15
15 · median 100
Started
2026
the only one that year
No phase
15 of 17
3 open now
Registered
17th of 17
by date

Among the 17 studies in Heart Failure by Edwards Lifesciences, this one is the 13th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 17th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 17 studies in Heart Failure by Edwards Lifesciences are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Heart Failure by Edwards Lifesciences, or all of them as a file.
02

Study summary

The objectives of this early feasibility study are to: evaluate initial clinical safety, device functionality, and effectiveness of the APTURE system for treatment of symptomatic HFrEF patients with elevated LAP, provide guidance for future clinical study and system designs utilizing the APTURE system.

Read the detailed description

This is a prospective, multi-center, open-label, single-arm, early feasibility study to evaluate the safety and performance of the APTURE system for the treatment of symptomatic HFrEF patients with elevated LAP.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Refined HFrEF Subgroup Inclusion Criteria:

  • A primary diagnosis of HFrEF ( ≤ 40%), and
  • Class II, III, or IVa heart failure symptoms and
  • Documentation of at least one of the following in the past 12 months, such as:

    • Hospitalization for heart failure; or
    • Increased treatment for heart failure, including intravenous (IV) or higher-dose diuretic therapy.
    • Elevated heart failure biomarker levels (BNP or NT-proBNP) within the past 6 months.

Note: Participants with NYHA Class II symptoms must have both a recent heart failure worsening event and elevated biomarker levels. Participants with NYHA Class III or IVa symptoms must have either a recent heart failure worsening event or elevated biomarker levels.

  • Stable Optimized GDMT- Maintained 6 months post-implant (includes stable GLP-1 RA), indicated device therapy, and comorbidity management.

Refined HFrEF Subgroup Exclusion Criteria:

  • Severe HF defined as one or more of the following:

    • Ambulatory NT-proBNP value >5,000 pg/ml or BNP value >1,600 pg/ml
    • Left ventricular end-diastolic diameter (LVEDD) >8 cm
    • Left ventricular ejection fraction (LVEF) \< 20%
    • ACC/AHA Stage D HF or non-ambulatory NYHA Class IV HF
    • Inotropic infusion (continuous or intermittent) within the past 6 months
    • Active listing on the cardiac transplant waiting list
  • More than mild right ventricular dysfunction
  • Valve disease

    • Mitral regurgitation > moderate
    • Mitral stenosis > mild
    • Tricuspid regurgitation > moderate
    • Aortic regurgitation > moderate
    • Aortic stenosis > moderate
  • (BMI) ≥45
  • Myocardial infarction and/or any therapeutic invasive, non-valvular cardiac procedure within the past 3 months, or current indication for coronary revascularization
  • Stroke, , deep vein thrombosis, or pulmonary embolus within the past 6 months
  • Cardiac resynchronization therapy implanted within the past 12 months, or unmet guideline-directed indication for CRT
  • Renal insufficiency as determined by serum creatinine (sCr) level >2.5 mg/dL or estimated (eGFR) \<25 ml/min/1.73 m2
  • Performance of the 6-minute walk test with a distance \<100 m or >450 m
  • Active endocarditis or infection requiring intravenous antibiotics within 3 months of scheduled index procedure
  • Presence of one or more of the following resting hemodynamic findings:

    1. Mean pulmonary capillary wedge pressure (PCWP) >35 mmHg
    2. Mean right atrial pressure (RAP) >15 mmHg
    3. Mean PCWP-mean RAP gradient \< 5 mmHg
    4. Pulmonary vascular resistance (PVR) ≥5 Wood Units (WU)
    5. Cardiac index \<1.8 L/min/m2
  • Baseline resting heart rate >100 bpm
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Edwards APTURE transcatheter shunt system

    Device: Edwards APTURE transcatheter shunt system

Interventions

  • DeviceEdwards APTURE transcatheter shunt system

    Transcatheter treatment of symptomatic heart failure patients with elevated left atrial pressure (LAP).

06

What researchers measure

Primary outcomes

  1. Rate of major cardiac/cerebrovascular/renal events and re-intervention (Safety Endpoint)

    Composite of device- or procedure-related major adverse cardiovascular, cerebrovascular, and renal events (MACCRE) at 30 days post implant procedure or hospital discharge, whichever is later.

    Time frame: 30 days

Secondary outcomes

  1. Change in KCCQ Overall Summary Score (Performance Endpoint)

    Change in KCCQ-OSS from baseline to 6 months.

    Time frame: 6 months

07

Study locations

2 of 3 sites recruiting
  • Herzzentrum Universitätsklinikum Köln
    Cologne, Germany 50937, Germany
    Not yet recruiting
  • Herzzentrum Dresden GmbH Universitätsklinik für Innere Medizin und Kardiologie
    Dresden, Germany 01307, Germany
    Recruiting
  • Johannes Gutenberg Universitaet Mainz
    Mainz, Germany 55131, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 4 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2032
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858799
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Mar 2032 (estimated)
Last update
Oct 5, 2026

Study contacts

Natalie Alon
Contact
Natalie_Alon@edwards.com
949-250-1898
Melissa Arteaga
Contact
melissa_arteaga@edwards.com
949-250-2002

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion